Multiple Myeloma

Long-term considerations for the detection and treatment of CRS and other adverse events when managing patients with multiple myeloma.

Expert panelists from Mayo Clinic discuss their approach for the use of BCMA and non-BCMA targeting bispecifics, respectively, in patients with relapsed/refractory multiple myeloma.

Expert perspectives on ensuring the early detection and treatment of CRS and other adverse events when initiating bispecific therapy in patients with multiple myeloma.

Noffar Bar, MD, details data on talquetamab in R/R MM treatment from the MonumenTAL-1 study, and Syed S. Ali, MD, speaks to his experience with teclistamab in clinical practice.

Elan Gorshein, DO, JD, MPH, explains his choice of frontline therapy for patients with relapsed/refractory multiple myeloma.

A panel of experts shares insight on treatment sequencing and selection in the setting of relapsed/refractory multiple myeloma.

Experts from Ochsner Health highlight treatment options for patients who present with transplant-ineligible newly diagnosed multiple myeloma.

Experts on multiple myeloma discuss the management of adverse effects from bispecific antibodies.

Experts on multiple myeloma offer clinical insights on treatment options and considerations for patients with standard- and high-risk multiple myeloma.

An expert panel discusses bispecific antibodies and their mechanisms of action in the treatment of relapsed/refractory multiple myeloma.

Nausheen Ahmed, MD, discusses the measurement of treatment response following induction therapy in patients with multiple myeloma.

Investigators anticipate sharing data from a phase 1/2a trial evaluating inobrodib on its own and in combination with pomalidomide and dexamethasone among patients with multiple myeloma at a future medical conference.

Data appear to support a tailored treatment approach with induction and post–autologous stem cell transplant consolidation daratumumab and CVRd in those with ultra-high–risk multiple myeloma.

A recent Satellite Sessions program hosted by CancerNetwork® brought together experts from different Ochsner Health campuses to discuss the diversity of practices among care providers regarding patient interactions and treatment choices.

Experts explain the strategies for optimal selection between different BCMA-targeting and non-BCMA-targeting bispecifics for the treatment of relapsed/refractory multiple myeloma.

Experts review recent data on non-BCMA-targeting bispecifics for the treatment of R/R MM.

The panel discusses how non-BCMA-targeting bispecifics might be selected and sequenced in MM.

Cindy Varga, MD, details her experience with sequencing BCMA-targeting agents for patients with relapsed/refractory multiple myeloma.

Key opinion leaders in multiple myeloma management address barriers inherent in the selection and use of bispecifics.

Focused discussion on the mSMART guidelines for monitoring and managing adverse events associated with bispecific therapies in patients being treated for relapsed/refractory multiple myeloma.

Experts Scott A. Soefje, PharmD, and Kirollos S. Hanna, PharmD, share their perspectives on initial steps in initiating bispecific therapy for patients with multiple myeloma.

A panel of key opinion leaders from Mayo Clinic reflect on optimizing use of bispecifics in relapsed/refractory multiple myeloma, reviewing step-up dosing, administration, and followup strategies.

Experts comment on the subset analysis of the MAIA study in the frail NDMM patient population.

Noffar Bar, MD, discusses the MAIA study investigating a daratumumab combination therapy in patients with transplant-ineligible multiple myeloma.

Black patients appear less likely than their White or Asian counterparts to meet hematologic lab criteria and treatment-related criteria necessary to enroll in clinical multiple myeloma trials.